503A pharmacies compound patient-specific prescriptions; 503B outsourcing facilities register with the FDA and compound in larger batches under cGMP.
Compounded semaglutide is dispensed by either a 503A pharmacy (patient-specific prescriptions) or a 503B outsourcing facility (FDA-registered, larger-batch, cGMP oversight). A transparent provider names its pharmacy so you can verify the license and category. Compounded semaglutide is not FDA-approved regardless of pharmacy type.
503A: patient-specific compounding under state board oversight. 503B: FDA-registered outsourcing facilities operating under cGMP, subject to FDA inspection.
A named, licensed pharmacy lets you verify sourcing and sterile-compounding standards (USP <797>). Providers that never name a pharmacy make verification impossible.
503A compounds patient-specific prescriptions; 503B is an FDA-registered outsourcing facility compounding larger batches under cGMP.
Check the state board of pharmacy license and, for 503B, the FDA registered-outsourcing-facility list.
Both operate under oversight; what matters most is that the pharmacy is named, licensed, and verifiable.
Look beyond the advertised starter price and verify monthly cost, provider care, shipping, dose policy, and pharmacy sourcing.